Published by Josh White on 17th March 2020
(Sharecast News) - Commercial-stage pharmaceutical company Shield Therapeutics updated the market on the 'AEGIS-H2H' clinical trial on Tuesday, the data of which was primarily designed to be used in health economic analyses, pricing and reimbursement applications, as well as marketing purposes.